Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended March 31, 1997
Business Overview: BD operates in Medical Supplies and Devices and Diagnostic Systems segments. The company reported strong operational performance driven by productivity improvements and a favorable product mix, despite headwinds from foreign currency translation and the absence of revenue from previously divested businesses.
Key Financial Metrics
| Metric | Q2 1997 | Q2 1996 | 6 Months 1997 | 6 Months 1996 |
|---|---|---|---|---|
| Revenues | $699.2 million | $705.7 million | $1,355.0 million | $1,345.7 million |
| Net Income | $82.7 million | $74.8 million | $140.8 million | $119.3 million |
| Earnings Per Share (Diluted) | $0.62 | $0.54 | $1.06 | $0.86 |
| Gross Profit Margin | 49.6% | 47.8% | 48.6% | 46.7% |
| Operating Income | $121.7 million | $112.8 million | $208.1 million | $184.7 million |
| Operating Margin | 17.4% | 16.0% | 15.4% | 13.7% |
| Cash from Operations (6mo) | N/A | $209.3 million | $179.2 million | |
| Total Debt (Short + Long Term) | $668.0 million | $695.6 million (Sep 30, 1996) | ||
| Cash and Equivalents | $151.3 million | $135.2 million (Sep 30, 1996) |
Material Changes vs. Prior Period
- Revenue Trends: Reported revenues were slightly flat year-over-year for both the quarter (-1%) and six months (+1%). However, management notes that organic growth was approximately 4% for the quarter and 6% for the six months when adjusting for a stronger U.S. dollar (estimated $20M negative impact in Q2) and the absence of revenue from divested businesses.
- Profitability Expansion: Gross profit margins improved by nearly 2 percentage points in both periods, driven by a more profitable product mix and productivity gains. Operating income increased 8% in Q2 and 12% for the six-month period.
- Segment Performance:
- Medical Supplies & Devices: Revenues were slightly down reported, but up ~5% (Q2) and ~8% (6mo) on an adjusted basis. Strong growth noted in injection systems and infusion therapy.
- Diagnostic Systems: Revenues were flat to slightly down reported, but up ~3% (Q2) and ~5% (6mo) adjusted. U.S. infectious disease diagnostics faced cost containment pressures, while international segments showed growth.
- Debt Reduction: Total debt declined by $28 million during the first six months of 1997. The debt-to-capitalization ratio improved to 33.4% from 36.0% a year ago.
Guidance, Outlook, and Risks
- Acquisitions: BD signed definitive agreements to acquire Difco Laboratories Inc. (estimated $82M annual revenue) and PharMingen (estimated $30M annual revenue). Both transactions are expected to close in fiscal 1997 pending government approval.
- Capital Allocation: The company repurchased 2.4 million shares for $108 million in the first six months. Authorization remains to acquire an additional 12.4 million shares. Capital expenditures for the full year are expected to be slightly higher than the prior year's $146 million.
- Accounting Changes: The company will adopt SFAS No. 128 (Earnings Per Share) for the quarter ended December 31, 1997, which will alter the calculation of basic and diluted EPS.
- Risks and Contingencies:
- Currency: Continued unfavorable impact from foreign currency translation on international revenues.
- Regulatory/Market: U.S. cost containment initiatives continue to impact the infectious disease diagnostics business.
- Tax Rate: The effective tax rate increased to 29.0% from 28.0% due to a less favorable mix of income among tax jurisdictions.
Investor Verification Checklist
- Verify the closing dates and regulatory approvals for the Difco Laboratories and PharMingen acquisitions.
- Monitor the impact of the stronger U.S. dollar on future international revenue growth.
- Review the specific product mix changes driving the 2% improvement in gross margins to ensure sustainability.
- Confirm the timeline for the adoption of SFAS No. 128 and its impact on reported EPS in the fourth quarter.
- Assess the remaining capacity for share repurchases given the $108M spent in the first half of the year.